AstraZeneca plc (AZN) Receives “Buy” Rating from Citigroup Inc.

Citigroup Inc. reaffirmed their buy rating on shares of AstraZeneca plc (LON:AZN) in a report issued on Monday morning.

A number of other equities analysts also recently commented on the stock. JPMorgan Chase & Co. reaffirmed a neutral rating and set a GBX 4,800 ($59.46) target price on shares of AstraZeneca plc in a research note on Thursday, July 21st. Jefferies Group lifted their target price on shares of AstraZeneca plc from GBX 4,600 ($56.98) to GBX 4,800 ($59.46) and gave the stock a hold rating in a research note on Thursday, July 14th. HSBC set a GBX 4,815 ($59.64) target price on shares of AstraZeneca plc and gave the stock a neutral rating in a research note on Tuesday, August 2nd. Beaufort Securities reaffirmed a hold rating on shares of AstraZeneca plc in a research note on Wednesday, August 10th. Finally, Goldman Sachs Group Inc. set a GBX 4,000 ($49.55) target price on shares of AstraZeneca plc and gave the stock a sell rating in a research note on Wednesday, August 10th. Five analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus target price of GBX 4,966.24 ($61.52).

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Shares of AstraZeneca plc (LON:AZN) opened at 4404.50 on Monday. The stock’s market cap is GBX 55.72 billion. The stock has a 50 day moving average of GBX 4,857.61 and a 200 day moving average of GBX 4,557.17. AstraZeneca plc has a 12 month low of GBX 3,680.00 and a 12 month high of GBX 5,505.00.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2016 Mideast Time.